Liver fibrosis: the 2017 state of art by Caviglia, GIAN PAOLO et al.
1 
 
 
 
 
 
This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 [Panminerva Medica, 2017, 10.23736/S0031-0808.17.03359-6] 
 ovvero [Caviglia GP, Rosso C, Fagoonee S, Saracco GM, Pellicano R, ed. Minerva 
Medica, 2017, pagg.1-12] 
The definitive version is available at: 
La versione definitiva è disponibile alla URL: 
[https://www.minervamedica.it/it/riviste/panminerva-medica/index.php] 
2 
 
Liver fibrosis: the 2017 state of art 
 
Gian Paolo CAVIGLIA 1, *, Chiara ROSSO 1, Sharmila FAGOONEE 2, Giorgio Maria SARACCO 1, 3, 
Rinaldo PELLICANO 3 
 
1Department of Medical Sciences, University of Turin, Turin, Italy 
2Institute for Biostructures and Bioimages-CNR c/o Molecular Biotechnology Center, University of 
Turin, Turin, Italy 
3Unit of Gastroenterology and Hepatology, Molinette Hospital, Turin, Italy 
 
*Corresponding author: Gian Paolo Caviglia, Department of Medical Sciences, University of Turin, 
10100 Turin, Italy. 
E-mail: caviglia.giampi@libero.it 
 
Conflict of interest. The authors certify that there is no conflict of interest with any financial 
organization regarding the material discussed in the manuscript. 
 
3 
 
Abstract 
Liver fibrosis is a wound-healing response to a wide spectrum of chronic liver injuries. It is 
characterized by loss of hepatocytes and alteration in hepatic architecture following an imbalance 
between extracellular matrix synthesis and degradation. Irrespectively of underlying etiology, fibrosis 
may progress to cirrhosis and specific pathogenetic mechanisms as well as different disease patterns 
may be identified according to etiology. 
Liver biopsy is still considered the gold standard for fibrosis assessment, despite the fact that it is 
invasive, has poor patient compliance and is not exempt of complications. Several reliable and non-
invasive tools are currently used in clinical practice, including imaging methods and surrogate serum 
biomarkers, commonly combined into composite scores. The main limitation of non-invasive methods 
is the low performance in the discrimination of intermediate stages of fibrosis. However, with the 
recent availability of novel treatment options, particularly for chronic hepatitis C, a precise staging of 
liver fibrosis is becoming clinically less relevant. Conversely, since patients with cirrhosis need to be 
monitored for the risk of hepatocellular carcinoma development, the accurate detection of this 
condition is a primary endpoint. 
Finally, several promising antifibrotic agents are under investigation in phase I and II trials. 
Nevertheless, further efforts are needed for the identification of novel potential targets for the 
development of antifibrotic drugs able to arrest, and possibly revert liver fibrogenesis. 
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The natural history of chronic hepatitis is characterized by long-lasting inflammation and 
hepatocellular necrosis that lead to fibrogenesis, which overtime progresses in a variable percentage of 
patients to cirrhosis. Prognosis and clinical management of patients with chronic hepatitis are strongly 
affected by the degree of liver fibrosis. Thus, accurate staging of fibrosis is crucial to assess the risk of 
evolution towards cirrhosis and its complications such as hepatocellular carcinoma (HCC) and liver 
failure both in viral and non-viral chronic liver diseases.1, 2 
Worldwide, the number of chronic hepatitis C virus (HCV) infected persons is estimated to be 
around 185 million, whereas approximately 248 million individuals are chronically infected with 
hepatitis B virus (HBV) despite decades of vaccination.3-5 Remarkably, in Western Countries, non-
alcoholic fatty liver disease (NAFLD) is becoming the most common liver disorder affecting 17%-46% 
of adults,6 and its progressive form (non-alcoholic steatohepatitis or NASH) accounts for 7%-30% of 
NAFLD patients.7  
Across the wide spectrum of liver diseases, long-term hepatic necro-inflammation is the 
common feature triggering liver fibrosis development and progression.8 However, several aspects 
related to etiology, genetics and epigenetics could impact pathogenesis, diagnosis and treatment.9-14 
In this paper, we focus on viral and metabolic types, and review the mechanisms of liver fibrogenesis, 
the currently available diagnostic tools and the potential novel therapies. 
 
Pathogenesis of liver fibrosis 
Liver fibrosis is a wound-healing response to a wide spectrum of chronic liver injuries and 
results from an imbalance between extracellular matrix (ECM) synthesis and degradation.15 Normally, 
ECM is composed of fibrillar collagens type I and III, and microfibrillar collagens type IV. Excessive 
ECM deposition, especially fibrillary collagens, causes an alteration of the normal hepatic architecture 
with progressive substitution of the liver parenchyma with scar tissue.16 
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The key factor of fibrogenesis is the activation and proliferation of myofibroblasts, with hepatic 
stellate cells (HSCs) being the major contributors of myofibroblast pool (82-96%).17 HSCs are non-
parenchymal quiescent cells residing in the space of Disse that normally account for 5-8% of total liver 
cells.18 The main functions of HSCs include vitamin A storage, sinusoidal blood flow regulation 
through endothelial cell interactions, xenobiotic detoxification, immune-tolerance regulation and ECM 
homeostasis.19 However, following pathological insults with consequent release of pro-fibrogenic 
cytokines and various growth factors, HSCs switch from a normal quiescent state to an activated 
myofibrobast phenotype.20 HSCs activation leads to loss of balance between matrix metalloproteinases 
(MMPs), which are zinc-dependent ECM degrading enzyme, and tissue inhibitors of metalloproteinase 
family (TIMPs), resulting in inhibition of ECM degradation.21 However, a disease specific pattern 
could be identified in fibrosis development. Chronic viral hepatitis is characterized by porto-central 
septa and interface hepatitis whereas NASH is distinguished by intercellular fibrosis and fibrillar ECM 
deposition around sinusoids.22 
 
Liver fibrosis in chronic hepatitis B 
The host immune system is tightly involved in liver disease pathogenesis.23 Besides 
inflammation, different viral factors are associated to viral hepatitis-related fibrosis and cirrhosis, 
particularly in chronic HBV infected patients in whom viral genotype and viral replication are the main 
factors that contribute to fibrosis progression.24, 25 In Asiatic populations, it has been reported that HBV 
genotype C is associated with more severe liver disease.26 Kao et al., in Taiwanese chronic hepatitis B 
(CHB) patients, investigating the relationship between HBV genotypes and liver disease severity, 
found that genotype C was prevalent in patients with cirrhosis (60% vs. 23%, p<0.001).24 Accordingly, 
Sumi et al. reported that among 258 patients with histologically verified chronic liver disease, the ratio 
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of patients with advanced fibrosis in genotype C was significantly higher than that in genotype B 
(22/74 vs. 30/40, respectively; p=0.034).27 On the contrary, a retrospective study involving 262 
Caucasian patients with chronic HBV infection (prevalent genotypes D and A, 27% and 24%, 
respectively) failed to demonstrate an association between a given HBV genotype and liver disease 
severity.28  
Beside HBV genotype, basal core promoter (BCP) mutations have been associated to liver 
disease progression. In particular, a sequential accumulation of BCP mutations have been reported 
during CHB natural history, with A1762T/G1764A mutations selected in the early course of infection, 
G1986A pre-core mutation during liver disease progression and mutations at nucleotides 1753 and 
1989 in the late course of chronic liver disease, with prevalence in patients with cirrhosis.29 Similarly, 
Chu  et al. found that A1762T/G1764A BCP mutant was associated with about 4-fold increased risk of 
cirrhosis30and, more recently, Tseng et al. reported that A1762T/G1764A BCP mutant percentage > 
45% was associated with an increased risk of cirrhosis development (adjusted odds ratio [OR]=2.81; 
95% confidence interval [CI]: 1.40-5.67).31 Interestingly, it has been indicated that such mutation 
affects codons 130 and 131 of the X gene (K130M and V131I) thus altering HBx protein and 
contributing to HCC development.32 In addition, it has been reported that HBx protein could activate 
HSCs in vitro through paracrine secretion of transforming growth factor (TGF)-β, a cytokine involved 
in fibrogenesis.32 Moreover, HSCs exposed to conditioned medium from HBx-expressing hepatocytes 
showed increased expression of fibrillar collagen type I, connective tissue growth factor (CTGF), α 
smooth muscle actin (αSMA) and MMP-2.33 Accordingly, Guo et al., investigating HBx effects on the 
proliferation and expression of fibrosis-related molecules in the human HSCs line (LX-2), found that 
HBx accelerated G1-S progression in LX-2 cells and that αSMA, TGF-β1, TGF-βRII, CTGF and 
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collagen I expression was significantly increased in the co-cultures of LX-2 cells with stable HBx 
transfected cell line.34 
Finally, viral replication plays a significant role in HBV-related liver fibrogenesis.35, 36 A 
population-based prospective cohort study, of 3582 untreated HBV-infected patients prevalently 
hepatitis B e antigen (HBeAg)-negative (3073/3582; 85.8%), showed that cumulative incidence of 
cirrhosis increased with HBV DNA level, ranging from 4.5% in patients with HBV DNA <300 
copies/mL to 36.2% in those with HBV DNA ≥106 copies/mL (p<0.001).24 In addition, the risk for 
cirrhosis was independent on HBeAg status and serum alanine aminotransferase (ALT) level.24 
However, two independent studies reported that in HBeAg-positive subjects, HBV DNA levels were 
inversely correlated to fibrosis degree,37 and that older age (OR=1.049; 95%CI: 1.017–1.083, p=0.003), 
elevated ALT (OR=0.766; 95%CI: 0.551–0.993, p=0.044), and lower HBV DNA levels (OR=1.011; 
95%CI: 1.004–1.018, p=0.003) are independently associated with significant fibrosis.38 Likely, in 
immune-reactive patients, an extensive immune-mediated response towards HBV may lead to both 
viral load suppression and liver inflammation resulting in hepatitis progression. Indeed, patients in 
immune-tolerant phase of HBV infection, exhibit high viral load but no inflammation, and 
consequently fibrosis. 
 
Liver fibrosis in chronic hepatitis C 
In chronic hepatitis C (CHC), immunological response is the major factor associated to liver 
disease progression. However, structural (core, E2) and non-structural (NS3 and NS5) HCV proteins 
may directly contribute to liver fibrogenesis through different pathways.39 It has been showed that 
HCV core protein could upregulate TGF-β1 in vitro.40 Both core protein and NS3 could induce TGF-β1 
expression through the generation of reactive oxygen species (ROS) and activation of p38 MAPK, 
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JNK, ERK1/2, NFκB-dependent pathways or stimulating the secretion of pro-inflammatory 
chemokines such as interleukin (IL)-8, MCP-1, and RANTES that may participate in inflammatory 
cells recruitment.41, 42 Recently, Li et al found that HCV NS5A-transactivated protein 13 (NS5ATP13) 
was upregulated in fibrotic liver tissues and was able to enhance ECM production and human HSCs 
activation, hence acting as a profibrogenic factor.43 The E2 glycoprotein of HCV envelope binding to 
CD81 of HSCs, induces a time-dependent increase in the synthesis and activity of MMP-2. 
Consequently, the increased ECM degradation may favor inflammatory infiltration and further 
parenchymal damage.44  
Unlike HBV viral factors, the role of HCV genotypes and HCV RNA levels in liver disease 
progression is marginal. Both genotype 1 and high viral load were predictor of non-response to 
interferon (IFN)-based treatment regimens, thus indirectly associated to liver disease progression.45, 46 
Conversely, it has been shown that different host factors including age of infection older than 40 years, 
alcohol consumption ≥50g/day, and male sex have a stronger association with fibrosis progression than 
virological factors in HCV infection.47 In addition, different host genetic variants are associated to a 
more rapid fibrosis progression.48 In particular, Tamaki  et al investigated the genetic risk factors 
associated with fibrosis progression by analyzing 176 CHC patients who did not achieve sustained 
virologic response to IFN-based therapy.49 The authors found a significant fibrosis progression rate in 
IL28B (rs8099917) TG/GG and PNPLA3 (rs738409) CG/GG carriers and both genotypes were 
independent predictors of rapid fibrosis progression at multivariate analysis (IL28B TG/GG hazard 
ratio [HR]: 3.9, p=0.001, and PNPLA3 CG/GG HR: 3.1, p=0.040).49 Similarly, Ali et al found that 
PNPLA3 CG/GG was significantly associated with the presence of cirrhosis (OR: 1.76; p<0.05) in a 
large cohort (n=937) of CHC patients.50 
9 
 
Finally, a recent study reported that differences in ECM turnover could reflect an etiology-
specific ECM composition during fibrogenesis in both CHB and CHC infections.51 Interestingly, the 
basement membrane biomarkers P4NP7s (marker of collagen type IV formation) and C4M (marker of 
MMP-degraded type IV collagen) were significantly elevated in CHB patients, whereas pro-C3 
(marker of collagen type III formation) was increased in CHC patients,51 suggesting that collagen 
deposition and remodeling depend on the type of viral insult, thus harboring potentially relevant 
pathogenetic and diagnostic implications.  
 
Liver fibrosis in non-alcoholic fatty liver disease 
NAFLD is a common cause of chronic liver disease strictly linked to obesity and diabetes. Most 
patients with NAFLD have simple fatty liver (NAFL), a benign and reversible condition that in a subset 
of patients may progress to a more severe form, NASH, characterized by the joint presence of steatosis, 
inflammation, ballooning degeneration with or without the presence of fibrosis. Mechanisms involved 
in the pathogenesis of NASH and in the development of fibrosis are poorly understood. 
The pathogenesis of NASH has been considered for a long time a “two hit” process.52 The first 
hit is the development of hepatic steatosis through the accumulation of triglycerides in hepatocytes, 
while the second hit includes a variety of inflammatory processes, such as oxidative stress, apoptosis, 
gut-derived stimulation and the release of pro-inflammatory cytokines from the adipose tissue that can 
potentially promote hepatic fibrogenesis.53 However, a recent genome-wide association study (GWAS) 
identified PNPLA3 as a key gene in the development of NASH indicating that  genetic background 
could significantly impact on the progression of the liver disease.54 Particularly, the single nucleotide 
polymorphism (SNP) rs738409_G risk allele, that is associated with both hepatic inflammation and 
steatosis, could explain why some populations are more prone to develop NASH. For example, 
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Hispanics show a higher (45%) prevalence of steatosis compared to European-Americans (33%) and 
African-Americans (24%). Furthermore, Hispanics show also a higher prevalence of NASH and 
cirrhosis while African-Americans are less predisposed to develop liver failure.54  
 
Lipotoxicity and fibrogenesis 
In the setting of NAFLD, fibrosis may develop independently of inflammation due to the direct 
pro-fibrogenic action of ROS.55 In NAFLD, ROS generation may derive from an altered metabolic 
state. Briefly, the impaired lipolysis in the adipose tissue caused by insulin resistance (IR), leads to an 
excessive release of free fatty acids (FFAs) that reach the liver. In the hepatocytes, FFAs surplus 
triggers lipoperoxidation thus favoring the development of ROS and their reactive intermediates, such 
as 4-hydroxy-2,3-nonenal (HNE), by the mitochondrial electron transport chain or other redox 
enzymes. Toxic lipids are able to activate several cellular stress pathways contributing to the 
endoplasmic reticulum (ER) stress, which is one of the most important factor for disease progression in 
patients with NASH.56, 57  
Furthermore, it has been reported that ROS, together with oxidized LDL, may activate HSCs 
thus promoting inflammation and fibrosis.58 Particularly, HNE is able to up-regulate the expression of 
several profibrogenic genes including pro-collagen type I, TIMP-1 and monocyte chemotactic protein 1 
(MCP-1 or CCL2) probably through the c-Jun N-terminal kinase (JNKs), activator protein-1 (AP-1) 
and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) molecular pathways.59 
 
Apoptosis and fibrogenesis 
Excessive oxidative stress induced by ROS results in apoptosis, a mechanism that contribute to 
the progression of different liver diseases.60-62 Inflammation, regeneration and fibrosis may all be 
11 
 
promoted by apoptosis of adjacent cells.63 Particularly, hepatic fibrosis has the potential to favor the 
development of cirrhosis, and eventually, HCC.16 Studies have shown that attenuation of hepatic 
apoptosis was able to reduce fibrogenesis while the blockage of the anti-apoptotic member of the B-cell 
lymphoma-2 (Bcl-2) family enhanced it.64, 65 The engulfment of apoptotic bodies by HSCs promotes 
fibrogenesis through the activation of nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2), 
the oxidase system in the phagocytes.64, 66 Activated HSCs also secrete MMPs mediating the release of 
tumor necrosis factor (TNF)-α in the blood, in turn activating other MMPs in a feed-forward damage 
response.67 
 
Gut-derived stimulation and fibrogenesis 
A large number of microbial species reside in the gastrointestinal tract, and gut microbiota 
dysbiosis is associated with diseases ranging from localized gastroenterologic disorders to neurologic, 
respiratory, metabolic, hepatic, and cardiovascular illnesses.68 
Gut microbiota is implicated in the pathogenesis and progression of NAFLD, through the so-
called gut-liver axis.69 Pathogen associated molecular patterns (PAMPs) (lipoproteins, bacterial DNA, 
double-stranded RNA), seem to play an important role in fibrogenesis through their interaction with 
toll-like receptors (TLR)s, on fibroblasts.70 This interaction promotes the differentiation of these cells 
into collagen-producing myofibroblasts in turn establishing a proinflammatory/profibrogenic condition 
leading to the activation of HSCs-expressing TLRs.71 In addition, microbiota changes may increase the 
intestinal permeability favoring the propagation of inflammatory signal from the gut to the portal 
circulation and the liver. The altered intestinal permeability in mouse models has been associated to 
oxidative stress, ER stress and gut-derived lipopolysaccharide (LPS), and seems to trigger 
inflammatory responses and progressive liver damage.72 Patients with NAFLD show increased 
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intestinal permeability due to the disruption of intercellular tight junctions in the intestine where the 
bacterial overgrowth is increased.73  
Recently, several studies established a link between the gut-liver axis and HCC development 
through the increase in deoxycholic acid, a gut bacterial metabolite able to damage DNA and to 
promote hepatocarcinogenesis.74 
 
Role of cytokines in fibrogenesis 
Several lines of evidence have shown that adipokines can be considered as active modulators of 
hepatic fibrogenesis due to their different expression in healthy subjects compared to those with 
metabolic abnormalities such as IR or diabetes. Moreover, obesity and IR are significantly associated 
with fibrosis in different chronic liver diseases.75 
Adiponectin showed hepato-protective and anti-fibrogenic effects in mice models of alcoholic 
steatohepatitis (ASH) and NASH.76 In the setting of NAFLD/NASH, pericellular fibrosis was more 
severe in adiponectin-deficient mice fed high fat diet compared to wild type mice.77 Furthermore, 
adiponectin may delay the progression of experimental NASH from cirrhosis to HCC.78 This anti-
fibrogenic effect is mainly due to the direct interaction of adiponectin with HSCs through specific 
receptors that in turn promote HSCs apoptosis.79, 80  
On the contrary, leptin shows a pro-fibrogenic effect through its action on HSCs, Kupffer cells 
(KC) and sinusoidal cells. Leptin up-regulates type I procollagen, enhances TGF-β pathway, induces 
the expression of TIMP-1, and stimulates HSCs proliferation and survival.81-83 In addition, leptin may 
stimulate the phagocytic activity of and cytokines release (for example TGF-β) by KC that in turn 
indirectly activate HSCs.84 
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Another cytokine that seems to be important in fibrogenesis is resistin even if its biological role 
is controversial.85 Resistin is expressed only in quiescent HSCs in mice, while in human, recombinant 
resistin up-regulates the expression of MCP-1 and IL-8 through the NF-kB pathway.86 
 
Role of genetics factors in fibrogenesis 
The PNPLA3 rs738409 C>G polymorphism is considered one of the main genetic risk factors 
involved in the development of NAFLD and its progression. PNPLA3 is expressed in the liver by both 
hepatocytes and HSCs where it is regulated by insulin levels (through the induction of sterol regulatory 
element binding protein-1c [SREBP-1c] and carbohydrate response element binding protein 
[ChREBP]) and by retinol levels, respectively.87 In both hepatocytes and HSCs, PNPLA3 protein is 
located in the membrane of lipid droplets and showed an hydrolyse activity against triglycerides and 
retinyl esters.87-89 The rs738409 polymorphism results in loss of function of the protein with liver fat 
retention in hepatocytes and retinol retention in HSCs. The latter modifies HSCs phenotype from 
quiescent retinol depot to activated myofibroblasts which begin to secrete collagen. In addition, the 
release of retinol from HSCs in turn contributes to their activation.90  
 
Diagnosis of liver fibrosis 
Liver biopsy 
Traditionally, liver biopsy was the only available tool enabling the assessment of liver fibrosis 
and inflammation, further providing additional information regarding steatosis and unexpected 
cofactors or comorbidities. To investigate inflammation activity grade and to stage the amount and type 
of liver fibrosis, many scoring systems have been proposed.1  
Liver biopsy is still considered the gold standard for fibrosis assessment, despite several 
limitations and risks that make it unsuitable for patients’ monitoring.91 With the novel accurate non-
14 
 
invasive tools, in the setting of chronic viral hepatitis, liver biopsy is performed only in case of 
contradictory results with non-invasive markers.92, 93 In addition, with the occurrence of direct acting 
antivirals (DAAs) for CHC that safely allow treatment even in patients with advanced cirrhosis, the 
detection and the accurate staging of liver fibrosis have become clinically less relevant.  
Conversely, liver biopsy is essential for the differentiation of simple fatty liver from NASH.94 Indeed, 
the diagnosis of NASH requires the simultaneous presence of steatosis, lobular inflammation and 
ballooning.95 
 
Imaging methods 
Different imaging methods have been developed to non-invasively assess the extent of liver 
fibrosis. However, all available methods rely on the measurement of liver stiffness (LS), which is an 
intrinsic property of the liver parenchyma. Among available methods, the most widely used and 
validated technique is transient elastography (TE) (Fibroscan®, Echosense, Paris, France),1, 96 that 
allows fibrosis assessment by measuring the velocity of an elastic shear wave propagation through the 
liver.97 Harder the liver tissue, faster the shear wave propagates.98 Liver stiffness measurement is 
expressed in KiloPascals (kPa), with ranges between 2.5 to 75 kPa, and related to the METAVIR score 
(F0-F4). The principal advantages of TE include good reproducibility and high performance for 
cirrhosis detection (area under the curve [AUC]>0.9), as reported by a large European study involving 
1257 patients with chronic liver disease.99 Conversely, for patients with low or mild fibrosis, TE 
accuracy is lower.100 However, importance of TE resides in ruling out advanced fibrosis/cirrhosis rather 
than exactly defining fibrosis stages. According to liver disease etiology, different cut-offs have been 
proposed for the diagnosis of cirrhosis: 12.5 kPa in HCV, 11.7 kPa in HBV, 10.3 kPa in NASH, 17.9 
kPa in biliary liver diseases and 22.7 kPa in alcoholic liver disease.101 
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Finally, TE is a rapid examination, easy to learn and perform. Boursier et al showed that a 
novice observer can obtain a reliable LS result after a single training session, irrespectively of 
professional status (novice/expert agreement for TE results varied with LS level: <9 kPa, r=0.49; ≥9 
kPa, r=0.87).102 However, unreliable results could be obtained in patients with narrow intercostal 
spaces, ascites and body mass index (BMI)>28 kg/m2.98, 103 Additional confounding factors include 
ALT flares, extra-hepatic cholestasis, congestive heart failure, excessive alcohol intake and non-fasting 
patient at the time of examination.104-108 
Besides TE, several real-time elastographic methods such as acoustic radiation force imaging 
(ARFI) and supersonic shear wave imaging (SSI) have been recently developed for liver fibrosis 
assessment.109  
Similarly to TE, ARFI and SSI provide LS quantitation by measuring the velocity of a local 
shear wave through liver tissue, but unlike TE, these methods are integrated on standard 
ultrasonography devices and explore a defined region of interest below liver capsule, free of large 
vascular structures, that can be adapted by the operator.110 Both methods show high accuracy for severe 
fibrosis/cirrhosis detection compared to TE (AUC≥0.9).111 However, in a study including 332 patients 
with or without liver disease, a significantly higher percentage of reliable measurements, defined as 
success rate ≥60% and an interquartile range <30%, was obtained using ARFI vs. TE and SSI (92.1% 
vs. 72.2%, p<0.001 and 92.1% vs. 71.3%, p<0.001, respectively).112 
 
Non-invasive biomarkers 
Liver fibrogenesis is a dynamic and continuous process arising from the balance between 
deposition and removal of ECM. Non-invasive biomarkers include two main categories: direct markers 
of fibrogenesis, as expression of either deposition or removal of liver ECM, and indirect markers, 
reflecting alterations in hepatic function induced by fibrosis, without a direct link with fibrogenesis.113 
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Direct markers include hyaluronic acid (HA), laminin, type IV collagen, type II collagen N-terminal 
peptide, MMPs and cytokines, such as TNF-α and TGF-β.114 Indirect markers are mainly obtained by 
combining together routinely performed blood tests for the calculation of composite scores such as 
aminotransferase (AST) to platelet ratio index (APRI), FibroTest®, Hepascore®, enhanced liver fibrosis 
(ELF®) score and NAFLD fibrosis score (NFS).96 
Overall, surrogate biomarkers are less accurate in detecting intermediate stages of fibrosis 
compared to cirrhosis. In addition, it has been shown that the combination of different biomarkers 
could improve diagnostic accuracy compared to a single marker alone.115 Rosso et al. reported that the 
combination of cytokeratin18-Aspartate396 and LS improved the performance for the detection of 
significant and advanced fibrosis in NAFLD/NASH patients compared to CK18-Asp396 or LS alone 
(Δ area under the curve [AUC]=0.033, p=0.024, and ΔAUC=0.046, p=0.008, respectively).115 In 
patients with CHC, the combination of serum type IV collagen, laminin, APRI, and albumin resulted in 
an AUC value of 0.831 for significant fibrosis, 0.791 for advanced fibrosis, and 0.881 for cirrhosis,116 
whereas in CHB, a combination of peptide ions (serum transferrin, complement component C3c and 
transferrin) identified by mass spectrometry-based multiple reaction monitoring, showed an AUC of 
0.848∼0.966 and 0.785∼0.875 for the identification of significant fibrosis (S2-S4 vs. S0-S1) and 
severe fibrosis (S3-S4 vs. S0-S2).117 
Besides novel proposed biomarkers or scores, APRI, FibroTest® and NFS are currently the most 
widely used and validated tests. Main surrogate serum biomarkers for non-invasive evaluation of liver 
fibrosis and their performance are reported in Table 1.113, 118-125 A meta-analysis including 33 studies 
with 8739 CHC patients, found a summary AUROC for APRI of 0.77, 0.80, and 0.83 for the diagnosis 
of significant fibrosis, severe fibrosis and cirrhosis respectively,126 whereas another meta-analysis 
including 1798 CHB patients reported mean AUROC values of 0.79 and 0.75 for significant fibrosis 
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and cirrhosis.127 FibroTest® showed a mean AUC of 0.81 and 0.90 for the detection of significant 
fibrosis and cirrhosis in patients with CHC (n=1679),128 and mean AUC of 0.84 and 0.90, respectively, 
in patients with CHB (n=1640).129 NFS was created and validated analyzing data of 733 patients with  
biopsy confirmed NAFLD and showed an AUC of 0.88 and 0.82 for severe fibrosis/cirrhosis detection 
both in estimation and validation cohort.123  
 
Therapeutic perspectives  
The primary approach for the treatment of hepatic fibrosis consists, first of all, in the 
elimination of the cause of liver disease, for example, by virus eradication, alcohol abstinence or 
through appropriate diet.130 In the setting of HCV, the therapeutic efficacy of DAA to delay the end-
stage complications is under evaluation.131, 132  
Several phase I and II trials are investigating the effect of different antifibrotic agents with 
promising results. Emricasan, a pan-caspase inhibitor, can reduce liver fibrosis in bile duct ligated 
mouse.133 Furthermore, in both HCV and NASH, Emricasan significantly reduces transaminases 
levels.134,135 Galectins are cell-surface glycoproteins involved in the regulation of cell migration and 
inflammatory signaling. Galectin inhibitors, such as GR-MD-02, have shown good safety and 
tolerability, and two phase II studies in patients with NASH and cirrhosis are ongoing to evaluate the 
efficacy.135 The farnesoid X receptor (FXR) agonist obeticholic acid, improves liver damage and shows 
beneficial effects on portal hypertension in both NASH and primary biliary cholangitis (PBC).136  
Vitamin E 800 IU/day, with its antioxidant properties, is used to improve steatosis and 
inflammation but its effect on fibrosis is currently under investigation.137 Unfortunately, vitamin E is 
not recommended to treat diabetic NASH patients with other chronic liver diseases. In addition to 
vitamin E, silybin, the main compound of the extract from sylibum marianum, is able to slow fibrosis 
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progression in different chronic liver diseases through its antioxidant, anti-inflammatory and 
antifibrotic properties.138 An Italian randomized placebo-controlled double-blind clinical trial 
conducted in 70 HCV patients, showed that the combination of pegylated-IFN plus ribavirin with 
silybin and vitamin E was able both to improve the antiviral response and to reduce serum markers of 
liver fibrosis through a direct antioxidant effect on the activation of HSCs.139 Another randomized trial 
conducted in 99 patients with biopsy proven NASH confirms the antifibrotic effects of sylibin but 
further studies in larger cohorts are required to define its optimum dosage and the correct duration of 
the treatment.140 Another antioxidant compound commonly used in traditional medicine is anthocyanin 
(from plants). In mice models of cholestatic liver damage and bile duct ligation, the decrease in the 
oxidative stress and lipid peroxidation improve both liver inflammation and fibrosis.141 Finally, lysyl 
oxidase monoclonal antibody simtuzumab is currently used in two phase II trials for the treatment of 
NASH patients with severe fibrosis/cirrhosis but its efficacy is scarce.142 
 
Conclusions 
The profound understanding of the pathogenetic mechanism of liver fibrosis together with the 
availability of reliable non-invasive tools for disease assessment allowed significant improvement of 
management of patients with chronic liver disease. Imaging methods such as transient elastography are 
currently widely adopted in clinical practice. Serum biomarkers of fibrosis are also well validated in 
patients with chronic viral hepatitis, despite being less well validated in NAFLD and in other chronic 
liver diseases. In this context, non-invasive tools permit a reliable detection of cirrhosis which is still a 
major clinical end-point; indeed, patients with liver cirrhosis should be monitored for the complications 
related to portal hypertension and screened for HCC development. There is, however, an urgent need to 
develop probes and contrast agents to non-invasively detect, when it is still reversible, the first signs of 
fibrosis through multimodal molecular imaging. 
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To date, the possibility to directly treat liver fibrosis remains an unmet need. Several therapeutic 
approaches are currently under investigation both at preclinical and clinical level, and have shown 
promising results. In the near future, the identification of novel potential targets for the development of 
antifibrotic drugs allowing either profibrogenic pathways inhibition or selective fibrolysis activation 
could provide powerful tools to arrest and even revert liver fibrosis. 
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Table I. Performance of surrogate serum biomarkers for non-invasive evaluation of significant liver 
fibrosis and cirrhosis. 
 
Abbreviations: γ-GT, gamma-glutamyltransferase; ALT, alanine aminotransferase: AST, aspartate 
aminotransferase; AUC, area under the curve; BMI, body mass index; HA, hyaluronic acid; IFG, 
impaired fasting glucose; TIMP-1, tissue inhibitor of metalloproteinase-1. 
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Figure 1. Mechanisms involved in the pathogenesis of hepatic fibrosis. 
 
In the setting of NAFLD, the impaired lipolysis in the adipose tissue due to insulin resistance leads to 
an increase flux of FFAs that from the adipose tissue reach the liver. In the liver, FFAs, in part promote 
the development of steatosis but an excess enhances lipoperoxidation and oxidative stress. Similarly, 
alcohol consumption and HCV infection contribute to the formation of ROS that, in turn may led to 
hepatic injury. The intestinal dysbiosis alters the gut microbiome and promotes the release of several 
PAMPs that can reach the liver and enhance HSCs activation. Genetic background seems to be 
involved in the onset and progression of hepatic fibrosis, mainly through the PNPLA3 rs738409 
variant. In chronic HBV infection, viral genotype and viral replication are the main factors that 
contributes to fibrosis progression. 
Abbreviations: aHSC, activated hepatic stellate cells; FFAs, free fatty acids; HBV, hepatitis B virus; 
HCV, hepatitis C virus; HSCs, hepatic stellate cells; IR, insulin resistance; ox-stress, oxidative stress; 
NAFLD, non-alcoholic fatty liver disease; PAMPs, pathogen associated molecular patterns; PNPLA3, 
patatin-like phospholipase domain-containing protein 3; qHSC, quiescent hepatic stellate cells; ROS, 
reactive oxygen species; TG, triglycerides.  
 
